Protocol for the measurement of the absorbed dose rate to water for a planar 32P beta emitting brachytherapy source: A multi-institutional validation
This is a multi-institutional report on inter-observer and inter-instrument variation in the calibration of the absorbed dose rate for a planar 32P beta emitting brachytherapy source. Measurement accuracy is essential since the dose profile is steep and the source is used for the treatment of tumors that are located in close proximity to healthy nervous system structures. (Source: Brachytherapy)
Source: Brachytherapy - October 24, 2021 Category: Cancer & Oncology Authors: Liana Mulet, Izabella Barreto, Gil'ad N. Cohen, Antonio L. Damato, Thomas Mauceri, Jennifer Pursley, Christopher L. Deufel Source Type: research

A novel use of 3D-printed template in vaginal HDR brachytherapy
The High-Dose-Rate (HDR) vaginal cylinder treatment is typically designed using the initial CT, while the subsequent implants are verified using rudimentary methods (i.e., visual inspection, ruler measurements, etc.) and/or X-ray imaging. We are proposing the use of a 3D-printed individualized template that could provide simple and reproducible vaginal cylinder insertion. (Source: Brachytherapy)
Source: Brachytherapy - October 24, 2021 Category: Cancer & Oncology Authors: Yixiang Liao, Ken Tatebe, Parul Barry, Dian Wang, Julius Turian Source Type: research

Time-resolved QA and brachytherapy applicator commissioning: Towards the clinical implementation
This study describes the use of a novel method, the Iridium Imaging System for QA (IrIS – QA), to automate and improve the applicator commissioning for HDR 192Ir brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - October 14, 2021 Category: Cancer & Oncology Authors: Gabriel P. Fonseca, Robert Voncken, Joep Hermans, Frank Verhaegen Source Type: research

125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer
To determine if patients with unfavorable intermediate-risk (UIR), high-risk (HR), or very high-risk (VHR) prostate cancer (PCa) treated with 125I interstitial brachytherapy benefit from androgen deprivation therapy (ADT). (Source: Brachytherapy)
Source: Brachytherapy - October 14, 2021 Category: Cancer & Oncology Authors: Timothy D. Smile, Martin C. Tom, Ahmed Halima, Jay P. Ciezki, Chandana A. Reddy, Kevin L. Stephans, Omar Y. Mian, Ryan X. Zhang, Eric A. Klein, Steven Campbell, James Ulchaker, Kenneth Angermeier K, Rahul D. Tendulkar Source Type: research

Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer
PURPOSE/OBJECTIVES To examine patient characteristics that predispose to higher opioid administration during tandem and ovoid (T&O) high-dose rate (HDR) brachytherapy.METHODS A single-institution retrospective review was performed on patients who underwent brachytherapy for cervical cancer. Patients were included if they received at least one fraction of HDR T&O brachytherapy with analgesia administration recorded in the Medication Administration Record. Fentanyl dose was dichotomized as “low” (mean (Source: Brachytherapy)
Source: Brachytherapy - October 4, 2021 Category: Cancer & Oncology Authors: Jessica M Wilson, Erik Davies, Xianming Tan, Wendy Brewster, Ellen Jones, Ashley A Weiner Source Type: research

Evaluation of dose differences between intracavitary applicators for cervical brachytherapy using knowledge-based models
Currently, there is a lack of patient-specific tools to guide brachytherapy planning and applicator choice for cervical cancer. The purpose of this study is to evaluate the accuracy of organ-at-risk (OAR) dose predictions using knowledge-based intracavitary models, and the use of these models and clinical data to determine the dosimetric differences of tandem-and-ring (T&R) and tandem-and-ovoids (T&O) applicators. (Source: Brachytherapy)
Source: Brachytherapy - October 1, 2021 Category: Cancer & Oncology Authors: Karoline Kallis, Jyoti Mayadev, Brent Covele, Derek Brown, Daniel Scanderbeg, Aaron Simon, Helena Frisbie-Firsching, Catheryn M. Yashar, John P. Einck, Loren K. Mell, Kevin L. Moore, Sandra M. Meyers Source Type: research

Computed tomography-guided partial-breast brachytherapy using implanted catheters as fiducial markers versus co-registered magnetic resonance imaging
Partial-breast irradiation (PBI) needs accurate cavity delineation with computed tomography (CT). In perioperative PBI using multicatheter-interstitial brachytherapy (MIB), catheters implanted during surgery were enabled as fiducial markers. Magnetic resonance imaging (MRI) can also assist delineation with CT. (Source: Brachytherapy)
Source: Brachytherapy - September 30, 2021 Category: Cancer & Oncology Authors: Kazuhiko Sato, Takahiro Shimo, Masahiro Kato, Nana Natsume, Hiromi Fuchikami, Naoko Takeda, Tomohiko Okawa Source Type: research

Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial
We report the long-term final results of a large randomized trial in terms of toxicities and efficacy. (Source: Brachytherapy)
Source: Brachytherapy - September 28, 2021 Category: Cancer & Oncology Authors: Umesh Mahantshetty, Shirley Lewis, Reena Engineer, Jamema Swamidas, Supriya Chopra, Lavanya Gurram, Rajesh Kinhikar, Deepak Deshpande, Christian Kirisits, Shyamkishore Shrivastava Source Type: research

Clinical values of transrectal ultrasound in judging GTV of cervical cancer
To investigate the clinical value of transrectal ultrasound in judging the Gross Target Volume (GTV) of cervical cancer (CC). (Source: Brachytherapy)
Source: Brachytherapy - September 26, 2021 Category: Cancer & Oncology Authors: Yuanqiang Lin, Peng Dong, Dan Shi, Zhuang Mao, Ning Zhang, Wenhui Li, Hui Wang, Guanghui Cheng, Xiaoli Wu Source Type: research

Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer
This study evaluated outcomes associated with a high-dose-rate (HDR) brachytherapy boost combined with stereotactic body radiation therapy (SBRT) for patients with higher-risk localized prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - September 26, 2021 Category: Cancer & Oncology Authors: Daniel Gorovets, Margaret Hopkins, Marisa Kollmeier, Assaf Moore, Arun Goel, Daniel Shasha, Victoria Brennan, Sean McBride, Gilad Cohen, Antonio L. Damato, Michael J. Zelefsky Source Type: research

ACR –ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy
This practice parameter aims to detail the processes, qualifications of personnel, patient selection, equipment, patient and personnel safety, documentation, and quality control and improvement necessary for an HDR brachytherapy program. (Source: Brachytherapy)
Source: Brachytherapy - September 26, 2021 Category: Cancer & Oncology Authors: Matthew M. Harkenrider, Kevin Albuquerque, Derek Brown, Mitchell Kamrava, Martin King, Firas Mourtada, Peter Orio, Rakesh Patel, Michael Price, Prema Rassiah, Abhishek A. Solanki, William Small, Naomi R. Schechter Source Type: research

Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy
GammaTile intracranial brachytherapy (cesium-131 seeds) has demonstrated encouraging safety and local control results, and recently received Food and Drug Administration clearance for newly diagnosed and recurrent brain tumors. The authors present the first reported case of GammaTile intraoperative brachytherapy performed during an awake craniotomy. (Source: Brachytherapy)
Source: Brachytherapy - September 26, 2021 Category: Cancer & Oncology Authors: Shearwood McClelland, Ulysses G Gardner, Yi Le, Sook Kien Ng, Mitesh V Shah, Gordon A Watson Source Type: research

Intensity modulated high dose rate ocular brachytherapy using Se-75
In this study, we computationally test this proposed design using MCNP6. (Source: Brachytherapy)
Source: Brachytherapy - September 21, 2021 Category: Cancer & Oncology Authors: Justine M Dupere, John J Munro, David C Medich Source Type: research

Management of locally advanced mesonephric carcinoma of the cervix in the setting of Mullerian Duct anomaly spectrum and unilateral renal agenesis: A case report and review of the literature
Cervical mesonephric adenocarcinoma is a rare histologic cervical carcinoma variant arising from remnants of the mesonephric duct. Few clinical cases have been reported in the literature, and given the low rate of occurrence, the optimal management strategy is unknown. Most reported cases involve patients with either early stage (FIGO I) or metastatic disease. Herein, we report the only known case of locally advanced, node-positive cervical mesonephric carcinoma in a 55-year old woman with Mullerian duct anomaly of the uterus, obstructed hemivagina, and ipsilateral renal agenesis. (Source: Brachytherapy)
Source: Brachytherapy - September 12, 2021 Category: Cancer & Oncology Authors: Tru-Khang T. Dinh, Elizabeth U. Parker, Kiran Gangadhar, Bahar Mansoori, Brandon A. Dyer Tags: Case report Source Type: research

Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement
The purpose of this guideline is to present evidence-based consensus recommendations for low dose rate (LDR) permanent seed brachytherapy for the primary treatment of prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - September 8, 2021 Category: Cancer & Oncology Authors: Martin T. King, Mira Keyes, Steven J Frank, Juanita M. Crook, Wayne M. Butler, Peter J. Rossi, Brett W. Cox, Timothy N. Showalter, Firas Mourtada, Louis Potters, Richard G. Stock, Marisa A. Kollmeier, Michael J. Zelefsky, Brian J. Davis, Gregory S. Merric Source Type: research

Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - September 1, 2021 Category: Cancer & Oncology Source Type: research

Masthead
(Source: Brachytherapy)
Source: Brachytherapy - September 1, 2021 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - September 1, 2021 Category: Cancer & Oncology Source Type: research

Palliative treatment with high-dose-rate endobronchial interventional radiotherapy (Brachytherapy) for lung cancer patients
: to report on the use of high-dose-rate (HDR) endobronchial interventional radiotherapy (brachytherapy, EBIRT) for palliation of symptoms in patients with lung cancer. (Source: Brachytherapy)
Source: Brachytherapy - August 21, 2021 Category: Cancer & Oncology Authors: Tamer Soror, Gy örgy Kovács, Sacha Wecker, Mahmoud Ismail, Harun Badakhshi Source Type: research

Utilization of brachytherapy in Quebec, Canada
Despite the excellent clinical outcomes from brachytherapy treatments compared with other modalities and the low associated costs, there have been reports of a decline in utilization of brachytherapy. The aim of this study was to investigate in detail the trend in utilization of brachytherapy in the province of Qu ébec, Canada, from 2011 to 2019. (Source: Brachytherapy)
Source: Brachytherapy - August 19, 2021 Category: Cancer & Oncology Authors: Magali Lecavalier-Barsoum, Farzin Khosrow-Khavar, Krum Asiev, Marija Popovic, Te Vuong, Shirin A. Enger Source Type: research

Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy
While brachytherapy is an effective treatment for localized prostate cancer, there has been a noticeable decline in its use. Training opportunity for prostate brachytherapy has been in steady decline, with some residents receiving little to no hands-on training. This work was developed to design a training environment that uses a phantom-based simulator to teach the process of TRUS-based prostate brachytherapy (Source: Brachytherapy)
Source: Brachytherapy - August 19, 2021 Category: Cancer & Oncology Authors: Amani Shaaer, Saad Alrashidi, Hans Chung, Andrew Loblaw, Gerard Morton, Moti Paudel, Chia-Lin Tseng, Ananth Ravi Source Type: research

PSA: Declining utilization of prostate brachytherapy
To analyze rates of brachytherapy use for prostate cancer over time and evaluate patient characteristics, demographics and factors predictive for its utilization. (Source: Brachytherapy)
Source: Brachytherapy - August 19, 2021 Category: Cancer & Oncology Authors: Lauren Andring, Alison Yoder, Todd Pezzi, Chad Tang, Rachit Kumar, Usama Mahmood, Gary V. Walker Source Type: research

Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer
Addition of a brachytherapy boost to external beam radiation therapy (EBRT) reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity. Whether brachytherapy boost technique, specifically low-dose-rate (LDR-BT) versus high-dose-rate (HDR-BT), impacts treatment-related toxicity is unclear. (Source: Brachytherapy)
Source: Brachytherapy - August 18, 2021 Category: Cancer & Oncology Authors: Vishal R. Dhere, Benjamin W. Fischer-Valuck, Subir Goyal, Yuan Liu, Tiffany M. Morgan, Elizabeth Ghavidel, Drew M. Moghanaki, Bruce W. Hershatter, Pretesh R. Patel, Ashesh B. Jani, Karen D. Godette, Peter J. Rossi, Sagar A. Patel Source Type: research

Knowledge-based dose prediction models to inform gynecologic brachytherapy needle supplementation for locally advanced cervical cancer
The use of interstitial needles, combined with intracavitary applicators, enables customized dose distributions and is beneficial for complex cases, but increases procedure time. Overall, applicator selection is not standardized and depends on physician expertise and preference. The purpose of this study is to determine whether dose prediction models can guide needle supplementation decision-making for cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - August 12, 2021 Category: Cancer & Oncology Authors: Karoline Kallis, Jyoti Mayadev, Kelly Kisling, Derek Brown, Daniel Scanderbeg, Xenia Ray, Katherina Cortes, Aaron Simon, Catheryn M. Yashar, John P. Einck, Loren K. Mell, Kevin L. Moore, Sandra M. Meyers Source Type: research

Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing
Integrated quality improvement (QI) and cost reduction strategies can help increase value in cancer care. Time-driven activity-based costing (TDABC) is a bottom-up costing tool that measures resource use over the full care cycle. We applied standard QI and TDABC methods to improve workflow efficiency and reduce costs for MRI-guided prostate brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - August 10, 2021 Category: Cancer & Oncology Authors: Nikhil G. Thaker, Rajat J. Kudchadker, James R. Incalcaterra, Tharakeswara K. Bathala, Robert S. Kaplan, Ankit Agarwal, Deborah A. Kuban, Benjamin D. Frank, Prajnan Das, Thomas W. Feeley, Steven J. Frank Source Type: research

Custom 3D-printed applicators for high dose-rate brachytherapy in skin cancer
This paper describes the protocol for the development of 3D-printed custom applicators in treating skin carcinoma, the evaluation of the materials used, and the methods for segmentation and rendering of the applicators. (Source: Brachytherapy)
Source: Brachytherapy - August 9, 2021 Category: Cancer & Oncology Authors: Ismael Membrive Conejo, Oscar Pera Cegarra, Palmira Foro Arnalot, Ana Reig Castillejo, Nuria Rodr íguez de Dios, Xavier Sanz Latiesas, Ramón M. Pujol Vallverdú, Jaume Quera Jordana, Enric Fernandez-Velilla Cepria, Victor Algara Muñoz, Manuel Algara L Source Type: research

Morbidity following image-guided brachytherapy for cervical cancer: Patient and treatment related factors
This retrospective study aims to assess factors associated with the occurrence of toxicity after brachytherapy (BT), as boost after external beam radiotherapy (EBRT) for treatment of invasive cervix carcinoma. (Source: Brachytherapy)
Source: Brachytherapy - August 8, 2021 Category: Cancer & Oncology Authors: Le Guevelou Jennifer, Kammerer Emmanuel, Lequesne Justine, Lerouge Delphine, Lecornu Marie, Loiseau C édric, Thariat Juliette, Balosso Jacques, Silva Marlon Source Type: research

Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016
To assess recent changes and disparities in utilization and costs of radiotherapy in Medicare beneficiaries with prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - August 8, 2021 Category: Cancer & Oncology Authors: Kumar Mukherjee, William Small, Richard Duszak Source Type: research

Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy
The purpose of this study was to evaluate for age, racial, and ethnic disparities among clinical studies where patients can potentially receive brachytherapy treatment. (Source: Brachytherapy)
Source: Brachytherapy - August 8, 2021 Category: Cancer & Oncology Authors: Colton Ladbury, Jason Liu, Jennifer Novak, Arya Amini, Scott Glaser Source Type: research

A primer on time-driven activity-based costing in brachytherapy
Emphasis on value-based healthcare has led to increasing use of time-driven activity-based costing (TDABC) across medical departments. When applied to brachytherapy, TDABC provides insight into differences in costs across various modes of therapy, the nuances that drive cost including institutional factors and involved personnel, and discrepancies in reimbursement which influence clinical practice. This is especially important with the new alternative payment model (APM) in radiation oncology which offers fixed reimbursement per 90-day episode of care. (Source: Brachytherapy)
Source: Brachytherapy - August 7, 2021 Category: Cancer & Oncology Authors: Ria Mulherkar, Andrew Keller, Timothy N. Showalter, Nikhil Thaker, Sushil Beriwal Tags: Review Article Source Type: research

Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy
To correlate changes in urinary patient-reported outcomes including the International Prostate Symptom Score (IPSS), acute urinary retention and urethral stricture with urethral dose in those treated with low dose rate (LDR) prostate brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - August 2, 2021 Category: Cancer & Oncology Authors: JC Farris, RT Hughes, CR Steber, TE Craven, BA Frizzell Source Type: research

Outcomes for posterior uveal melanoma: Validation of American Brachytherapy Society Guidelines
To assess outcomes of small and medium choroidal melanoma (less than 5.0 mm in height) following Iodine-125 episcleral brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - July 23, 2021 Category: Cancer & Oncology Authors: Kyle Meidenbauer, Zachary Richards, Renato J. Yupari, James F. Bena, Allan Wilkinson, John Suh, Arun D. Singh Source Type: research

American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy
We present updated guidelines from the American Brachytherapy Society regarding the utilization of brachytherapy in the management of STS. (Source: Brachytherapy)
Source: Brachytherapy - July 21, 2021 Category: Cancer & Oncology Authors: Shauna R. Campbell, Chirag Shah, Jacob G. Scott, Nathan Mesko, Lukas Nystrom, Matthew Kolar, Abel Cordoba Largo, Mitchell Kamrava, Firas Mourtada, Arash O. Naghavi, Louis B. Harrison Source Type: research

Cost-effectivess of SpaceOAR system during prostate cancer radiation therapy: Really helpful or excess of expectations?
Recently Patel AK et al. (1) have retrospective evaluated acute patient-reported bowel quality of life (QOL) and rectal bleeding in prostate cancer patients (69 patients) treated with combination external beam radiation (EBRT), low-dose-rate brachytherapy (LDR-BT), and SpaceOAR (a hydrogel absorbable spacer). They concluded that with combination EBRT, LDR-BT, and SpaceOAR, bowel QOL returned to the baseline 3 months after LDR-BT and a clinically significant rectal bleeding less than 5%. This clinical experience highlights how the use of SpaceOAR system rapidly increasing in recent years. (Source: Brachytherapy)
Source: Brachytherapy - July 19, 2021 Category: Cancer & Oncology Authors: Jacopo Giuliani, Francesco Fiorica Tags: Letter to the Editor Source Type: research

Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technology
In this study, the commissioning and performance evaluation of the new real-time prostate high-dose-rate brachytherapy investigational system from Philips Disease Management Solutions integrating EMT was performed before its clinical integration. (Source: Brachytherapy)
Source: Brachytherapy - July 14, 2021 Category: Cancer & Oncology Authors: Marie-Claude Lavall ée, Audrey Cantin, Fanny Monéger, Martine Lefebvre, William Foster, Eric Vigneault, Luc Beaulieu Source Type: research

Radiation dose rate variations in different measurement scenarios after prostate 125I brachytherapy
This study aimed to directly compare different measurement scenarios using a supplemental radiation exposure measurement data set. (Source: Brachytherapy)
Source: Brachytherapy - July 14, 2021 Category: Cancer & Oncology Authors: Takashi Hanada, Atsunori Yorozu, Riki Kikumura, Toshio Ohashi, Naoyuki Shigematsu Source Type: research

Determination of Ir-192 micrselectron-V2 HDR/PDR dwell position reproducibility using a slit camera
To examine the limits of dwell position reproducibility of an ELEKTA microSelectron-V2 HDR/PDR remote afterloader. (Source: Brachytherapy)
Source: Brachytherapy - July 10, 2021 Category: Cancer & Oncology Authors: Don Robinson Source Type: research

Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc
To investigate local and systemic outcomes after enucleation, brachytherapy with ruthenium-106, iodine-125, notched and non-notched plaques and transpupillary thermotherapy (TTT) of choroidal melanomas touching the optic disc. (Source: Brachytherapy)
Source: Brachytherapy - July 9, 2021 Category: Cancer & Oncology Authors: Maria Fili, Melvin Astrahan, Gustav St ålhammar Source Type: research

Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement
The Radiation Oncology Alternative Payment Model (RO Model) will test prospective radiotherapy episode-based payments for 16 common disease sites. We created an automated analytics platform to calculate the impact of the RO Model vs historical fee-for-service episode reimbursements for brachytherapy treatments within five community oncology practices for prostate, uterine, and cervical cancer. (Source: Brachytherapy)
Source: Brachytherapy - July 5, 2021 Category: Cancer & Oncology Authors: Nikhil G. Thaker, Rehman Meghani, Cassandra Wilson, Jody Garey, Philip Nelson, Gautam H. Thaker, Chirag Shah, Peter Orio, Catheryn M. Yashar, Vivek Kavadi Source Type: research

PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study
To evaluate the PSA outcomes and the late patient's reported health related quality of life (HRQOL) and toxicity after single-fraction High-Dose-Rate brachytherapy (HDRB) and Low-Dose-Rate brachytherapy (LDRB) for prostate cancer. (Source: Brachytherapy)
Source: Brachytherapy - July 5, 2021 Category: Cancer & Oncology Authors: Thomas Reynaud, Lara Hathout, Damien Carignan, Maroie Barkati, Andr é-Guy Martin, William Foster, Frédéric Lacroix, Guila Delouya, Daniel Taussky, Gerard Morton, Eric Vigneault Source Type: research

Acute and late complications and toxicities of skin brachytherapy
Skin cancer is the most prevalent malignancy, and its incidence is rising. Surgery is the primary treatment, however, morbidity of surgical resection in certain parts of the body warrant alternate treatment options such as radiation therapy. Complex topology of the skin can pose a challenge for treatment with photon and electron external beam radiotherapy techniques. Brachytherapy can be an attractive radiotherapy technique for these regions. Furthermore, brachytherapy results in lower dose to the underlying deep organs. (Source: Brachytherapy)
Source: Brachytherapy - July 4, 2021 Category: Cancer & Oncology Authors: Amandeep S. Taggar, Paveen Mann, Alexandra Stewart, Phillip Devlin, Anna Likhacheva Tags: Review Article Source Type: research

Intravascular coronary brachytherapy combined with a drug-coated balloon
Coronary artery disease leads to stenosis of the major cardiac vessels, resulting in ischemia and infarction. Percutaneous intervention (PCI) with balloon angioplasty can re-open stenosed vessels. Drug eluting stents (DES) and intravascular brachytherapy (IVBT) and drug-coated balloons (DCBs) are proven to decrease the likelihood of another restenosis after PCI, but neither is completely effective. Due to the limited long-term effectiveness of IVBT or DCB used separately for salvage PCI, we combined the two in some poor prognosis patients. (Source: Brachytherapy)
Source: Brachytherapy - July 2, 2021 Category: Cancer & Oncology Authors: Kathleen E. Kearney, Kent Wallner, Minsun Kim, Ravi S. Hira, Edward Y. Kim, Kenta Nakamura, Upendra Parvathaneni, Zachary L. Steinberg, James M. McCabe, William L. Lombardi, Mark L. Phillips, Creighton Don Source Type: research

Editorial Board
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

Masthead
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

Table of Contents
(Source: Brachytherapy)
Source: Brachytherapy - July 1, 2021 Category: Cancer & Oncology Source Type: research

How to design, fabricate, and validate a customized COMS-style eye plaque: Illustrated with a narrow-slotted plaque example
A customized Collaborative Ocular Melanoma Study (COMS)-style eye plaque may provide superior dosimetric coverage compared with standard models for certain intraocular tumor locations and shapes. This work provides a recipe for developing and validating such customized plaques. (Source: Brachytherapy)
Source: Brachytherapy - June 30, 2021 Category: Cancer & Oncology Authors: Christopher L. Deufel, Lauren A. Dalvin, Jing Qian, Birjoo Vaishnav, Jordan McCauley Cutsinger, Michelle Neben Wittich, Ivy A. Petersen Tags: Technical Note Source Type: research

Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry
PURPOSE: Tilting of the posterior plaque margin during eye plaque brachytherapy can lead to tumor underdosing and increased risk of local recurrence. We performed a quantitative analysis of the dosimetric effects of plaque tilt as a function of tumor position, basal dimension, height and plaque type using 3D treatment planning software.MATERIALS AND METHODS: Posterior and anterior tumors with largest basal dimensions of 6, 12 and 18 mm and heights of 4, 7 and 10 mm were modeled. Both Eye Physics and COMS plaques were simulated and uniformly loaded. (Source: Brachytherapy)
Source: Brachytherapy - June 28, 2021 Category: Cancer & Oncology Authors: Matthew T. Studenski, Arnold Markoe, Stuart E. Samuels, Zelia M. Correa, Elizabeth Bossart, J. William Harbour Source Type: research

Quantifying clinical severity of physics errors in high-dose rate prostate brachytherapy using simulations
To quantitatively evaluate through automated simulations the clinical significance of potential high-dose rate (HDR) prostate brachytherapy (HDRPB) physics errors selected from our internal failure-modes and effect analysis (FMEA). (Source: Brachytherapy)
Source: Brachytherapy - June 27, 2021 Category: Cancer & Oncology Authors: David Aramburu Nunez, Michael Trager, Joel Beaudry, Gilad N. Cohen, Lawrence T. Dauer, Daniel Gorovets, Nima Hassan Rezaeian, Marisa A. Kollmeier, Brian Leong, Patrick McCann, Matthew Williamson, Michael J. Zelefsky, Antonio L. Damato Source Type: research

Geographic access to brachytherapy services in the United States
Disparities in geographic access to medical care exist in nearly all fields of medicine including radiation oncology. We aim to update knowledge of the geographic distribution of radiation oncologists in the United States. (Source: Brachytherapy)
Source: Brachytherapy - June 18, 2021 Category: Cancer & Oncology Authors: James E Bates, Nikhil G. Thaker, Akash Parekh, Trevor J Royce Source Type: research

In reply to Giuliani et al.
To the Brachytherapy Editorial Office, (Source: Brachytherapy)
Source: Brachytherapy - June 14, 2021 Category: Cancer & Oncology Authors: Ankur K. Patel, Sushil Beriwal Source Type: research